O
GPCR icon

OrbiMed’s Structure Therapeutics GPCR Stock Holding History

OrbiMed’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-150,000
Closed -$2.6M – 107
2025
Q1 		$2.6M Hold
150,000
– – 0.06% 88
2024
Q4 		$4.07M Buy
+150,000
New +$5.32M 0.08% 91

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

OrbiMed's GPCR Position: Q2 2026 in Review

OrbiMed increased its Structure Therapeutics (GPCR) stake by 50% in Q2 2026, buying an estimated $32.5M and bringing the position to 2,209,400 shares worth $119M. The position accounts for 2.2% of the portfolio, ranked #7.

OrbiMed first reported a position in GPCR in Q2 2024 and has held it in 9 quarters since. 191 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • OrbiMed held 2,209,400 shares of Structure Therapeutics worth $119M as of Q2 2026.
  • OrbiMed bought 733,997 Structure Therapeutics shares in Q2 2026, an estimated $32.5M.
  • Structure Therapeutics made up 2.2% of OrbiMed's portfolio in Q2 2026, its #7 holding.
  • OrbiMed first reported a position in Structure Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 191 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.